Nyxoah S.A.
General ticker "NYXH" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $162.9M (TTM average)
Nyxoah S.A. does not follow the US Stock Market performance with the rate: -22.8%.
Estimated limits based on current volatility of 1.9%: low 1.18$, high 1.22$
Factors to consider:
- Total employees count: 153 (-16.8%) as of 2025
- Current price 53.3% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.37$, 6.84$]
- 2026-12-31 to 2027-12-31 estimated range: [2.19$, 6.28$]
Financial Metrics affecting the NYXH estimates:
- Negative: with PPE of -1.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 17.37 > 2.08
- Positive: Interest expense per share per price, % of 1.12 <= 1.42
- Positive: 34.41 < Shareholder equity ratio, % of 41.47 <= 42.26
- Positive: 0.90 < Industry operating cash flow per share per price (median), % of 1.58
Short-term NYXH quotes
Long-term NYXH plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €4.35MM | €4.52MM | €10.02MM |
| Operating Expenses | €49.45MM | €63.33MM | €92.96MM |
| Operating Income | €-45.10MM | €-58.81MM | €-82.94MM |
| Non-Operating Income | €0.45MM | €2.38MM | €-6.13MM |
| Interest Expense | €1.21MM | €1.90MM | €1.69MM |
| R&D Expense | €27.66MM | €34.33MM | €42.82MM |
| Income(Loss) | €-44.66MM | €-56.43MM | €-89.08MM |
| Taxes | €0.00MM | €0.00MM | €1.01MM |
| Net Income(Loss)* | €-43.21MM | €-59.24MM | €-90.12MM |
| Stockholders Equity | €98.02MM | €113.25MM | €49.11MM |
| Inventory | €3.31MM | €4.72MM | €4.66MM |
| Assets | €124.16MM | €158.41MM | €118.43MM |
| Operating Cash Flow | €-44.78MM | €-49.23MM | €-67.50MM |
| Capital expenditure | €10.96MM | €6.07MM | €0.80MM |
| Investing Cash Flow | €32.01MM | €-16.32MM | €26.17MM |
| Financing Cash Flow | €16.86MM | €77.44MM | €38.79MM |
| Earnings Per Share** | €-1.55 | €-1.81 | €-2.36 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.